Premier Research
Parexel brings 40 years and 22,000+ staff to early-access and oncology development (560+ oncology studies, 104,000 patients, 26,000 sites, 50+ countries over five years), while Premier Research's Virtual Research Group supports late-phase and named-patient programs with remote and hybrid trial delivery.
- Country
- United States
us
cro
late-phase
Coverage
| CN | EU | US | |
|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Named-patient programs & compassionate use | market-access-commercial | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.